Biotech entity
Every one of those 2 sits in a single category, pharma. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 3.5 original sources each against 2.6 for the same window.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 3.5 original sources each against 2.6 for the same window. At 5.5, the average consequence score sits below the same-window beat average of 6. We currently track 2 Biotech stories that mention BioMarin Pharmaceutical, published between February 19, 2026 and February 20, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 36 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BioMarin Pharmaceutical. Shared-story counts are live from our verified record — not editorial picks.
Summit Therapeutics and its mid-cap biotech peers are set to report Q4 2025 results, with investor focus centered on Summit's ivonescimab commercialization path and BioMarin's Voxzogo expansion. These reports will serve as a critical barometer for the sector's ability to transition from R&D-heavy pipelines to sustainable commercial growth.
The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.
Source: admin (in) · prnewswire.com
BioMarin Pharmaceutical is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
